Hypercoagulable states

Hematology/Oncology Clinics of North America

Volumn 14, Issue 2, 2000, Pages 355-377

  Whiteman, Terence ^b   Hassouna, Houria I ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRIN; FIBRINOGEN; PROTHROMBIN;

BLOOD CLOTTING DISORDER; DISEASE ASSOCIATION; FEEDBACK SYSTEM; GENE MUTATION; GENETIC DISORDER; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOSIS;

EID: 0034095158     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70138-6     Document Type: Article

References (64)

1. K. Aakiyama K. Nakamura I. Makino Antithrombin III producing hepatocellular carcinoma Thromb Res 72 1993 193 201
2. C. Alessandri S. Basili F. Boili Hypercoagulability state in patients with chronic obstructive pulmonary disease Thromb Haemost 72 1994 343 346
3. H. Andrew M. David M. Adams Venous thromboembolic complications (VTE) in children: First analysis of the Canadian Registry of VTE Blood 83 1994 1251 1257
4. A. Azar J. Deckers P. Rosendaal Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients Thromb Haemost 72 1994 347 351
5. H. Beving S. Eksborg R. Malmgren Inter-individual variation of the effect of low dose aspirin regime on platelet cyclooxygenase activity Thromb Res 74 1994 39 51
6. M. Boisclair D. Lane H. Philippou Mechanisms of thrombin generation during surgery and cardiopulmonary bypass Blood 82 1993 3350 3357
7. Bounameaux H. De Moerloose P. A. Pierrier Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: An overview Thromb Haemost 71 1994 1 6
8. M. Cushman F. Bhushan E. Bovill Plasma resistance to activated protein C in venous and arterial thrombosis Thromb Haemost 72 1994 643 651
9. D Dahl, T Pedersen, P Klerulf et al. Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery. Thromb Res 70:451–458.
10. B. Dahlback The protein C anticoagulant system: Inherited defects a basis for venous thrombosis Thromb Res 77 1995 1 43
11. DVTENOX Study Group Markers of hemostatic system activation in acute deep venous thrombosis—Evolution during the first days of heparin treatment Thromb Haemost 70 1993 909 910
12. J. Fenton F. Ofosu Thrombin-mediated events implicated in post-thrombotic recovery Maraqoudakis M.E. Angiogenesis: Molecular Biology, Clinical Aspects 1994 Plenum Press New York 253 263
13. G. Finazzi T. Barbui Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S Thromb Haemost 71 1994 15 18
14. J. Francis D. Francis G. Gunathilagan Assessment of hypercoagulability in patients with cancer using the Sonoclot Analyzer and thromboelastography Thromb Res 74 1994 335 346
15. S. Frebelius U. Hedin J. Swedenborg Thrombogenicity of injured vessel wall—Role of antithrombin and heparin Thromb Haemost 71 1994 147 153
16. S. Gandrille B. Jude M. Alhenc-Gelas Compound heterozygosity in a family with protein C deficiency illustrating the complexity of the underlying molecular mechanism Thromb Haemost 70 1993 747 752
17. A. Garcia-Avello L. Garcia-Frade C. Gandarias High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA Thromb Res 73 1994 109 115
18. M. Gari L. Falkon T. Urrutia The influence of low protein S plasma levels in young women, on the definition normal range Thromb Res 73 1994 149 152
19. J.S. Ginsberg S. Demers P. Brill-Edwards Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolpin antibodies: Evidence for a prothrombotic state Blood 81 1993 2958 2963
20. M. Gordge R. Faunt P. Rylance Plasma D-dimer: A useful marker of fibrin breakdown in renal failure Thromb Haemost 61 1989 522 525
21. F. Green A. Hamsten M. Blomback The role of B-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden Thromb Haemost 70 1993 915 920
22. A. Halim H. Kahayama E. Maradny Coagulation in vivo microcirculation and in vitro caused by endothelin Thromb Res 72 1993 203 209
23. A. Hamsten The hemostatic system and coronary heart disease Thromb Res 70 1993 1 38
24. M. Hanss B. Coppere E. Gineyts Increased plasma free gamma carboxyglutamic acid levels during deep vein thrombosis and intravascular disseminated coagulation Thromb Res 73 1994 185 192
25. T. Hayashi J. Nichioka T. Shigekeyo Protein S Tokushima: Abnormal molecule with a substitution of Glu for lys-155 in the second epidermal growth factor-like domain of protein S Blood 83 1994 683 690
26. H. Hemker G. Williams S. Beguin A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes Thromb Haemost 56 1986 9 17
27. A. Henschen Human fibrinogen-structural variants and functional sites Thromb Haemost 70 1993 42 47
28. Herren T. Werner Straub P. A. Haeberli Prothrombin fragment 1 and 2, thrombin-antithrombin III complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency Thromb Haemost 71 1994 49 53
29. O. Huach L. Jorgenson T. Kolle Plasma cross-linked fibrin degradation products fraction D in patients undergoing elective abdominal surgery Thromb Res 51 1998 385 389
30. S. Ibbotson S. Gough P. Rice The effect of short-term exercise on plasma procoagulant activity in patients with type II (non-insulin dependent) diabetes and healthy volunteers Thromb Res 71 1993 149 158
31. K. Jochmans W. Lissens R. Vervoort Antithrombin-Gly 424 Arg: A novel point mutation responsible for type 1 antithrombin deficiency and neonatal thrombosis Blood 83 1994 146 151
32. M. John M. Elms E. O'Reilly The simpli RED D-dimer test: A novel assay for the detection of cross-linked fibrin degradation products in whole blood Thromb Res 58 1990 273 281
33. S. Khuri J. Loscalzo P. Ellis The platelet function defect of cardiopulmonary bypass Blood 82 1993 107 117
34. R. Kijowski D. Hoppensteadt J. Walenga Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin Thromb Res 74 1994 53 64
35. J. Koopman F. Haverkate P. Koppert New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody J Lab Clin Med 109 1987 75 84
36. C. Leroy-Matheron M. Gouault-Heilmann Influence of conditions of blood sampling on coagulation activation markers (prothrombin fragment 1 and 2, thrombin-antithrombin complexes and D-dimer) measurements Thromb Res 74 1994 399 407
37. L. Liu Z. Lin Z. Shen Changes of von Willebrand factor and antithrombin III levels in acute stroke: Differences between thrombotic and haemorrhagic stroke Thromb Res 72 1993 353 358
38. M. Meissner R. Manzo R. Bergelin Venous diameter and compliance after deep venous thrombosis Thromb Haemost 72 1994 372 376
39. K. Minamikawa H. Wada Y. Wakita Increased activated protein C–protein C inhibitor complex levels in patients with pulmonary embolism Thromb Haemost 71 1994 192 194
40. E. Moor A. Hamsten M. Blomback Haemostatic factors and inhibitors and coronary artery bypass grafting: Preoperative alterations and relations to graft occlusion Thromb Haemost 72 1994 335 342
41. H. Nielsen S. Husted L. Krusell Anticoagulant in deep venous thrombosis: A randomized controlled study Thromb Res 73 1994 215 226
42. G. Noll B. Lammle F.L. Duckert Plasmin inhibitors and fibrinogen breakdown during the initial phase of thrombolytic treatment—The problem of alpha-2-antiplasmin determination Thromb Res 51 1984 334 337
43. L. Norris J. Bonnar The invert effect of aspirin on increased whole blood platelet aggregation in oral contraceptive users Thromb Res 74 1994 309 315
44. F.A. Ofosu Molecular markers of in vivo coagulation and thrombosis Poller L. Recent Advances in Blood Coagulation, vol 6 1993 Churchill Livingstone London 51 68
45. I. Pabinger P. Kyrle H. Heisteinger Risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency Blood 83 1994 683 690
46. I. Pabinger B. Schneider Thrombotic risk of women with hereditary antithrombin II-protein C and proteins S benefit from taking oral contraceptive medication Thromb Haemost 71 1994 548
47. M. Petus B. Plaat H. Tencate Enhanced thrombin generation in children with sickle cell disease Thromb Haemost 71 1994 169 172
48. D. Prisco R. Daniccia F. Bonechi Evaluation of new methods for the selective measurement of fibrin and oxygen degradation products Thromb Res 56 1989 547 551
49. H. Rahr J. Sorensen P. Danielsen Markers of coagulation and fibrinolysis in blood Drawn into citrate with and without D-phe-pro-arg-chroromethyeketone (PPACK) Thromb Res 73 1994 279 284
50. M. Rees Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis Thromb Res 71 1993 337 359
51. G. Roth D. Calverley Aspirin, platelets, and thrombosis: Theory and practice Blood 83 1994 885 898
52. M. Seigneur P. Dufoureq C. Conri Levels of plasma thrombomodulin are increased in atheromatous arterial disease Thromb Res 71 1993 423 431
53. K. Serizawa T. Urano Y. Kozima The potential role of platelet PAI-1 in t-PA mediated clot lysis of platelet rich plasma Thromb Res 71 1993 289 300
54. M. Shimada T. Matsumata T. Kamakura Moderation of coagulation and fibrinolysis in hepatic resection: A randomized prospective control study using antithrombin III concentrates Thromb Res 74 1994 105 114
55. H. Simank M. Simon C.H. Bode Clinical usefulness of D-dimer: Evaluation during fibrinolytic treatment of venous thrombosis or myocardial infraction Thromb Res 56 1989 541 546
56. Y. Takada T. Urano I. Watanabe Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus Thromb Res 71 1993 405 458
57. J. Teitel K. Bauer H. Lau Studies of the prothrombin activation pathway utilizing radio immunoassays for the F2/F1+2 fragment and thrombin–antithrombin complex Blood 59 1982 1086 1095
58. J. Tomczak R. Ando H. Sobel Genetic analysis of a large kindred exhibiting type 1 protein C deficiency and associated thrombosis Thromb Res 74 1994 243 254
59. Van Genderen P. M. Gomes J. Stibbe The reliability of Hickman catheter blood for the assessment of activation markers of coagulation and fibrinolysis in patients with hematological malignancies Thromb Res 73 1994 247 254
60. Wachtfogel Y. DeLa Cadena R. R. Colman Structural biology, cellular interactions and pathophysiology of the contact system Thromb Res 72 1993 1 21
61. C.T. Weissbach J. Harenberg J. Wendesch Tissue factor pathway inhibitor in infants and children Thromb Res 73 1994 441 446
62. B. Woodhams P. Kernoff Problems with antisera specificity in immunoassays for human fibrinopeptide A Thromb Res 42 1986 689 693
63. J. Yamamoto I. Ishii Y. Okada Effect of leukocyte products on platelet thrombus formation, coagulation and spontaneous thrombolysis, as measured from native human blood in vitro Thromb Res 71 1993 281 287
64. D. Zitain Z. Bara M. Samama Compared activity of human, rat, and rabbit plasma tissue factor pathway inhibitors Thromb Res 72 1993 269 274